Summary of panelists with disclosed industry-related financial conflicts of interest, by type of guideline producer
| Type of guideline producer | No. of panelists, mean ± SD (range) | No. (%) of CPGs with COI statement for panelists | % of panelists with disclosure of industry-related FCOI,* mean ± SD (range) | Panel chair with industry-related FCOI | Panel vice-chair with industry-related FCOI |
|---|---|---|---|---|---|
| Government-sponsored organizations (n = 3) | 11 ± 8.5 (4–23) | 2 (67) 0 (0%) of 2 CPGs having panelists with FCOI | 0 | Chair not identified, n = 1 (33%) COI statement not available, n = 1 (33%) FCOI disclosed, n = 0 (0%) No FCOI disclosed, n = 1 (33%) | Vice-chair not identified, n = 2 (67%) COI statement not available, n = 1 (33%) FCOI disclosed, n = 0 (0%) No FCOI disclosed, n = 0 (0%) |
| Disease or condition interest groups (n = 9) | 33.9 ± 21.3 (5–81) | 8 (89) 8 (100%) of 8 CPGs having panelists with FCOI | 57 ± 27 (5–100) | Chair not identified, n = 3 (33%) COI statement not available, n = 1 (11%) FCOI disclosed, n = 5 (56%) No FCOI disclosed, n = 0 (0%) | Vice-chair not identified, n = 5 (56%) COI statement not available, n = 1 (11%) FCOI disclosed, n = 2 (22%) No FCOI disclosed, n = 1 (11%) |
| Medical professional societies (n = 9) | 13.1 ± 10.3 (3–37) | 6 (67) 4 (67%) of 6 CPGs having panelists with FCOI | 53 ± 45 (0–100) | Chair not identified, n = 4 (44%) COI statement not available, n = 2 (22%) FCOI disclosed, n = 3 (33%) No FCOI disclosed, n = 0 (0%) | Vice-chair not identified, n = 7 (78%) COI statement not available, n = 0 (0%) FCOI disclosed, n = 2 (22%) No FCOI disclosed, n = 0 (0%) |
Note: COI = conflict of interest, CPG = clinical practice guideline, FCOI = financial conflict of interest, SD = standard deviation.
↵* Of guidelines with a COI statement.